Borwell 658W, DHMC
The Center for Genomic Medicine is excited to have John Mulvihill, M.D., FACMG, Professor of Pediatrics and Kimberly V. Talley Chair in Medical Genetics, Children's Medical Research Institute, The University of Oklahoma Health Sciences Center, as our September Grand Rounds speaker!!
Talk title: "Germ cell mutation in cancer survivors: Using solidarity and population registries"
Date: Friday, September 15, 2017
Lecture: 11:00 - 12:00 p.m.
Q&A: 12:00 - 12:30 p.m.
Location: Borwell 658W, DHMC
Cancer treatment causes somatic cell mutations, so offspring of cancer survivors would seem likely to have an excess of genetic disorders, a manifestation of germ cell mutation. Several studies in the U.S., Denmark, and Finland show no excess to date, despite good power and the advantage of population-based registries of cancer and other outcomes.
Dr. Mulvihill is a pediatrician and medical geneticist with 20 years' experience at the National Cancer Institute, where he was chief of the Clinical Genetics Section of the Clinical Epidemiology Branch and Director of the Interinstitute Medical Genetics Program of the National Institutes of Health (NIH). In 1990, he became founder, chair, and professor of Human Genetics at the University of Pittsburgh and Co-director of the Pittsburgh Genetics Institute. In 1998, he accepted the Children’s Medical Research Institute--Kimberly V. Talley Chair of Genetics, Professor of Pediatrics, University of Oklahoma; he is also adjunct professor of Epidemiology and Biostatistics and of Pathology. In 2014, he became part-time consultant to the National Human Genome Research Institute.
A graduate of the College of the Holy Cross, Dartmouth Medical School, and the University of Washington, he was on the house staff at University of Washington Hospital and the Johns Hopkins Hospital. A member of 13 professional societies, he was co-founder and past president of the International Genetic Epidemiology Society. In addition to participation on the editorial boards of 17 scientific journals, he was co-editor-in-chief of Genetic Epidemiology and editor of the Neurofibromatosis Research Newsletter and The ACMG Medical Geneticist. In 1989, the National Neurofibromatosis Foundation awarded him its first Friedrich von Recklinghausen award. Medical ethics and mentoring are major commitments.
Dr. Mulvihill’s research has focused on the genetics of human cancer, with an emphasis on late genetic and reproductive effects in cancer survivors and on germ cell mutagenesis. He maintains a unique Registry of Pregnancies Exposed to Cancer Chemotherapy. He organized the first International Conferences on the Genetics of Human Cancer in 1975 and on Neurofibromatosis in 1980 and, in Oklahoma City in 2003, an International Conference on Family Cancer. He has had National Institutes of Health and other national research grants for neurofibromatosis, pancreatic cancer, and fetal alcohol syndrome and has written 336 scientific articles and edited 7 monographs and 8 board review course syllabi. Elected a Director of the American College of Medical Genetics, he is also a member of the Committee on Ethics, Law, and Society of the International Human Genome Organisation (HUGO) and a past Scientific Advisor of the Radiation Effects Research Foundation, Hiroshima and Nagasaki, Japan.
***Please silence your pagers and leave your laptops in your office out of
courtesy to the speaker and other attendees.***
CME credit for in-person attendees:
You must sign-in at the event for attendance verification.
Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Dartmouth-Hitchcock designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
We welcome all suggestions you have for future topics and invited speakers.